Lumos has announced that it has now received its largest purchase order to-date for FebriDx®, with its U.S. exclusive distribution partner PHASE Scientific placing an order valued at US$1.3 million.
This order marks an early step in the commercial rollout of FebriDx® in the United States, following CLIA waiver which expanded the product’s addressable market to more than US$1.0 billion annually.
Lumos CEO Doug Ward, commented:
"Receiving our largest order to-date, so soon after the granting of CLIA waiver is a strong validation of the commercial opportunity for FebriDx® in the US market. We look forward to supporting PHASE as it scales its commercial rollout and drives adoption of FebriDx® across the much broader pool of urgent and primary care settings."
